Background: Unipharm’s decision over Sanofi may change patent realm

Lod District Court Judge Ofer Groskopf precedent-setting ruling in favor of Unipharm and against Sanofi could shift the balance of economic risk of overly aggressive claiming of new patents in the patent arena from generic drug competitors to drug developers.

Groskopf’s ruling could have a major impact on the drug and patent markets in Israel and even overseas.

It could potentially empower generic competitors to challenge drug developers over questionable patent-extensions and possibly even leading to class-action lawsuits against developers for artificially keeping drug prices high.


Leave a Reply

Your email address will not be published. Required fields are marked *